OCGN - NASDAQ

Ocugen, Inc.

OCGN·NASDAQ

$1.30

-5.1%

HealthcareBiotechnology

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$440.08M

EPS-0.2300

P/E Ratio-5.65

Earnings Date07/30/2026

ocgn

Cash and Cash Equivalents

Last Annual Value

18.57M

3-Year CAGR

-38%

5-Year CAGR

-5%

10-Year CAGR

-5%

Adjust for Inflation

Ocugen, Inc. Competitors Analysis of Cash and Cash Equivalents

OCGN · NASDAQ

Company	Cash and Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
Ocugen, Inc. NASDAQ:OCGN	18.57M	-22.2%	-27.8%	-5.3%
Compass Therapeutics, Inc. NASDAQ:CMPX	30.64M	8.1%	-26.7%	N/A
Alumis Inc. Common Stock NASDAQ:ALMS	89.67M	24.9%	N/A	N/A
Lineage Cell Therapeutics, Inc. AMEX:LCTX	40.79M	4.8%	-6.1%	6.3%
Neurogene Inc. NASDAQ:NGNE	103.84M	-11.2%	8.0%	12.4%
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	182.53M	-21.3%	-14.9%	N/A
Omeros Corporation NASDAQ:OMER	9.66M	10.8%	-37.4%	15.8%
Fulcrum Therapeutics, Inc. NASDAQ:FULC	197.53M	97.7%	41.0%	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	169.74M	52.9%	47.8%	N/A
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	34.33M	15.2%	-11.7%	-20.6%

Ocugen, Inc. Fair Value Envelope

OCGN · NASDAQ

Our analysis suggests that OCGN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.3, this represents a potential HIDDEN relative to our calculated worth for Ocugen, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.3

Related Guides

Blog Categories

Continue your OCGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.